Last reviewed · How we verify
nicotine patch plus nicotine gum/lozenge
Nicotine patches and gum/lozenges deliver nicotine through different routes to bind nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cravings during smoking cessation.
Nicotine patches and gum/lozenges deliver nicotine through different routes to bind nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cravings during smoking cessation. Used for Smoking cessation in adults.
At a glance
| Generic name | nicotine patch plus nicotine gum/lozenge |
|---|---|
| Also known as | NRT |
| Sponsor | University of Minnesota |
| Drug class | Nicotine replacement therapy (NRT) combination |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
The combination therapy uses transdermal (patch) and oral (gum/lozenge) nicotine delivery to provide sustained baseline nicotine levels while allowing flexible supplemental dosing for breakthrough cravings. Both formulations activate nicotinic acetylcholine receptors, particularly in the mesolimbic reward pathway, mimicking some effects of smoked nicotine and easing the transition away from tobacco dependence.
Approved indications
- Smoking cessation in adults
Common side effects
- Skin irritation (patch)
- Mouth/throat irritation (gum/lozenge)
- Hiccups
- Nausea
- Headache
- Insomnia
- Dizziness
Key clinical trials
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- Mobile Contingency Management for Smoking Cessation (NA)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
- Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: